6.99
-1.89(-21.28%)
Currency In USD
| Previous Close | 8.88 |
| Open | 6.41 |
| Day High | 7.13 |
| Day Low | 6.23 |
| 52-Week High | 16.44 |
| 52-Week Low | 5.79 |
| Volume | 51.38M |
| Average Volume | 4.31M |
| Market Cap | 1.52B |
| PE | -4.92 |
| EPS | -1.42 |
| Moving Average 50 Days | 11.55 |
| Moving Average 200 Days | 10.96 |
| Change | -1.89 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $845.22 as of February 18, 2026 at a share price of $6.99. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $358.09 as of February 18, 2026 at a share price of $6.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
GlobeNewswire Inc.
Feb 13, 2026 10:00 PM GMT
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL,
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
GlobeNewswire Inc.
Jan 21, 2026 12:00 PM GMT
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD,
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
GlobeNewswire Inc.
Dec 08, 2025 12:00 PM GMT
Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approval